128 related articles for article (PubMed ID: 21269821)
1. The glutathione transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) increases temozolomide efficacy against malignant melanoma.
Tentori L; Dorio AS; Mazzon E; Muzi A; Sau A; Cuzzocrea S; Vernole P; Federici G; Caccuri AM; Graziani G
Eur J Cancer; 2011 May; 47(8):1219-30. PubMed ID: 21269821
[TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo efficacy of 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) on human melanoma.
Pellizzari Tregno F; Sau A; Pezzola S; Geroni C; Lapenta C; Spada M; Filomeni G; Bonanno E; Federici G; Caccuri AM
Eur J Cancer; 2009 Sep; 45(14):2606-17. PubMed ID: 19665369
[TBL] [Abstract][Full Text] [Related]
3. The cyclin-dependent kinase inhibitor PHA-848125 suppresses the in vitro growth of human melanomas sensitive or resistant to temozolomide, and shows synergistic effects in combination with this triazene compound.
Caporali S; Alvino E; Starace G; Ciomei M; Brasca MG; Levati L; Garbin A; Castiglia D; Covaciu C; Bonmassar E; D'Atri S
Pharmacol Res; 2010 May; 61(5):437-48. PubMed ID: 20026273
[TBL] [Abstract][Full Text] [Related]
4. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol, a specific glutathione S-transferase inhibitor, overcomes the multidrug resistance (MDR)-associated protein 1-mediated MDR in small cell lung cancer.
Filomeni G; Turella P; Dupuis ML; Forini O; Ciriolo MR; Cianfriglia M; Pezzola S; Federici G; Caccuri AM
Mol Cancer Ther; 2008 Feb; 7(2):371-9. PubMed ID: 18281520
[TBL] [Abstract][Full Text] [Related]
5. A strong glutathione S-transferase inhibitor overcomes the P-glycoprotein-mediated resistance in tumor cells. 6-(7-Nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol (NBDHEX) triggers a caspase-dependent apoptosis in MDR1-expressing leukemia cells.
Turella P; Filomeni G; Dupuis ML; Ciriolo MR; Molinari A; De Maria F; Tombesi M; Cianfriglia M; Federici G; Ricci G; Caccuri AM
J Biol Chem; 2006 Aug; 281(33):23725-32. PubMed ID: 16769721
[TBL] [Abstract][Full Text] [Related]
6. Poly(ADP-ribose) glycohydrolase inhibitor as chemosensitiser of malignant melanoma for temozolomide.
Tentori L; Leonetti C; Scarsella M; Muzi A; Vergati M; Forini O; Lacal PM; Ruffini F; Gold B; Li W; Zhang J; Graziani G
Eur J Cancer; 2005 Dec; 41(18):2948-57. PubMed ID: 16288862
[TBL] [Abstract][Full Text] [Related]
7. Structural basis for the binding of the anticancer compound 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol to human glutathione s-transferases.
Federici L; Lo Sterzo C; Pezzola S; Di Matteo A; Scaloni F; Federici G; Caccuri AM
Cancer Res; 2009 Oct; 69(20):8025-34. PubMed ID: 19808963
[TBL] [Abstract][Full Text] [Related]
8. The integrin antagonist cilengitide increases the antitumor activity of temozolomide against malignant melanoma.
Tentori L; Dorio AS; Muzi A; Lacal PM; Ruffini F; Navarra P; Graziani G
Oncol Rep; 2008 Apr; 19(4):1039-43. PubMed ID: 18357394
[TBL] [Abstract][Full Text] [Related]
9. IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.
Ramcharan R; Aleksic T; Kamdoum WP; Gao S; Pfister SX; Tanner J; Bridges E; Asher R; Watson AJ; Margison GP; Woodcock M; Repapi E; Li JL; Middleton MR; Macaulay VM
Oncotarget; 2015 Nov; 6(37):39877-90. PubMed ID: 26497996
[TBL] [Abstract][Full Text] [Related]
10. The glutathione S-transferase inhibitor 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio)hexanol overcomes the MDR1-P-glycoprotein and MRP1-mediated multidrug resistance in acute myeloid leukemia cells.
Ascione A; Cianfriglia M; Dupuis ML; Mallano A; Sau A; Pellizzari Tregno F; Pezzola S; Caccuri AM
Cancer Chemother Pharmacol; 2009 Jul; 64(2):419-24. PubMed ID: 19288261
[TBL] [Abstract][Full Text] [Related]
11. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological inhibition of poly(ADP-ribose) polymerase (PARP) activity in PARP-1 silenced tumour cells increases chemosensitivity to temozolomide and to a N3-adenine selective methylating agent.
Tentori L; Muzi A; Dorio AS; Scarsella M; Leonetti C; Shah GM; Xu W; Camaioni E; Gold B; Pellicciari R; Dantzer F; Zhang J; Graziani G
Curr Cancer Drug Targets; 2010 Jun; 10(4):368-83. PubMed ID: 20464779
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of temozolomide and hyperthermia on human melanoma cell growth and O6-methylguanine-DNA methyltransferase activity.
Pagani E; Falcinelli S; Pepponi R; Turriziani M; Caporaso P; Caporali S; Bonmassar E; D'Atri S
Int J Oncol; 2007 Feb; 30(2):443-51. PubMed ID: 17203227
[TBL] [Abstract][Full Text] [Related]
14. New cytotoxic agents for the treatment of metastatic malignant melanoma: temozolomide and related alkylating agents in combination with guanine analogues to abrogate drug resistance.
Spiro T; Liu L; Gerson S
Forum (Genova); 2000; 10(3):274-85. PubMed ID: 11007934
[TBL] [Abstract][Full Text] [Related]
15. Targeting glutathione-S transferase enzymes in musculoskeletal sarcomas: a promising therapeutic strategy.
Pasello M; Manara MC; Michelacci F; Fanelli M; Hattinger CM; Nicoletti G; Landuzzi L; Lollini PL; Caccuri A; Picci P; Scotlandi K; Serra M
Anal Cell Pathol (Amst); 2011; 34(3):131-45. PubMed ID: 21673434
[TBL] [Abstract][Full Text] [Related]
16. 6-(7-nitro-2,1,3-benzoxadiazol-4-ylthio) hexanol: a promising new anticancer compound.
Sha HH; Wang Z; Dong SC; Hu TM; Liu SW; Zhang JY; Wu Y; Ma R; Wu JZ; Chen D; Feng JF
Biosci Rep; 2018 Feb; 38(1):. PubMed ID: 29358310
[TBL] [Abstract][Full Text] [Related]
17. NBDHEX re-sensitizes adriamycin-resistant breast cancer by inhibiting glutathione S-transferase pi.
Sha H; Zou R; Lu Y; Gan Y; Ma R; Feng J; Chen D
Cancer Med; 2023 Mar; 12(5):5833-5845. PubMed ID: 36266920
[TBL] [Abstract][Full Text] [Related]
18. Systemic administration of GPI 15427, a novel poly(ADP-ribose) polymerase-1 inhibitor, increases the antitumor activity of temozolomide against intracranial melanoma, glioma, lymphoma.
Tentori L; Leonetti C; Scarsella M; D'Amati G; Vergati M; Portarena I; Xu W; Kalish V; Zupi G; Zhang J; Graziani G
Clin Cancer Res; 2003 Nov; 9(14):5370-9. PubMed ID: 14614022
[TBL] [Abstract][Full Text] [Related]
19. Potentiation of antiglioma effect with combined temozolomide and interferon-beta.
Park JA; Joe YA; Kim TG; Hong YK
Oncol Rep; 2006 Dec; 16(6):1253-60. PubMed ID: 17089046
[TBL] [Abstract][Full Text] [Related]
20. NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells.
Rocha CR; Kajitani GS; Quinet A; Fortunato RS; Menck CF
Oncotarget; 2016 Jul; 7(30):48081-48092. PubMed ID: 27344172
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]